Company Overview of BIND Therapeutics, Inc.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. The company’s lead Accurin drug candidate includes BIND-014, a prostate-specific membrane antigen targeted Accurin that contains docetaxel and is in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. It has collaboration agreements to develop Accur...
325 Vassar Street
Cambridge, MA 02139
Founded in 2006
Key Executives for BIND Therapeutics, Inc.
Chief Executive Officer
Total Annual Compensation: $395.0K
Total Annual Compensation: $247.9K
Compensation as of Fiscal Year 2013.
BIND Therapeutics, Inc. Key Developments
BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3w Dosing Schedule for Patients with Non-Small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium
Nov 19 14
BIND Therapeutics, Inc. presented positive results from its ongoing Phase 2 study of BIND-014 in non-small cell lung cancer (NSCLC), demonstrating it has met the primary objective in the once every three weeks (Q3W) arm as measured by overall response rate (ORR). The data demonstrate that BIND-014 is well-tolerated with clinically meaningful anti-tumor activity at a lower dose than conventional docetaxel in patients with advanced or metastatic NSCLC. BIND-014 also demonstrates promising anti-tumor activity in patients with tumors expressing KRAS mutations (mutated Kirsten ras oncogene homolog). KRAS mutations in NSCLC are generally associated with poor response to currently available drug therapy regimens, including docetaxel. An additional signal was observed in patients with squamous cell carcinomas, a major NSCLC subtype poorly served by existing available therapies. These data were presented at the 26(th) EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The Q3W dosing arm of the open label, multicenter, Phase 2 study enrolled 40 patients with advanced metastatic NSCLC who were treated with 60 mg/m(2) of BIND-014 on Day 1 of a 21-day cycle and achieved the following preliminary results: Five patients (13%, N=40) achieved a partial response with a median duration of response of 5.2 months and median progression free survival (PFS) of 2.7 months. There was one unconfirmed partial response that was not included in the analysis per RECIST v1.1.; Nine patients were enrolled with a confirmed KRAS mutation and two of those nine experienced an objective response (22%); median PFS in patients with KRAS mutant tumors was 2.7 months; In patients with squamous cell carcinoma (n=9) there were no confirmed objective responses; however, median PFS in patients with squamous cell carcinoma was 2.8 months. Prolonged (>4 cycles) disease control was also noted in six of nine (66%) patients with squamous histology; Preliminary median overall survival was 6.2 months for all patients treated, 9.6 months in patients with KRAS mutant tumors and 11.1 months in patients with squamous cell carcinoma; and twenty-one of 40 patients received four or more cycles of therapy, attesting to the tolerability of BIND-014. Consistent with previous results, neutropenia, anemia, neuropathy, and alopecia, commonly observed with docetaxel, were significantly reduced with BIND-014.
BIND Therapeutics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 03:55 PM
Nov 6 14
BIND Therapeutics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 03:55 PM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Scott L. Minick, Chief Executive Officer, President and Director.
BIND Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
Nov 6 14
BIND Therapeutics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of $3,365,000 compared to $4,566,000 a year ago. The decrease in revenue was the result of the completion of the Amgen collaboration in the second quarter of 2014. Loss from operations was $7,593,000 compared to $7,062,000 a year ago. Net loss attributable to common stock holders was $7,277,000 or $0.44 per basic and diluted share compared to $8,335,000 or $2.46 per basic and diluted share a year ago.
For the nine months, the company reported revenue of $7,389,000 compared to $8,831,000 a year ago. Loss from operations was $24,328,000 compared to $13,691,000 a year ago. Net loss attributable to common stock holders was $24,043,000 or $1.46 per basic and diluted share compared to $23,290,000 or $8.97 per basic and diluted share a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|